Senores Pharmaceuticals reported robust FY26 growth, with consolidated revenue rising 58.85% to Rs 632.63 Cr and profit after tax more than doubling to Rs 121.53 Cr. The company significantly expanded its US market footprint through the acquisition of Apnar Pharma and the launch of new joint ventures. Investors should note the company's aggressive portfolio expansion, with approved ANDAs jumping from 26 to 51, and its focus on scaling API self-sufficiency to drive future margins.
Senores Pharmaceuticals FY26 Profit Surges 108% to Rs 121.53 Crore
Revenue grew 58.85% year-on-year to Rs 632.63 Cr, while Profit After Tax (PAT) reached Rs 121.53 Cr.
Reader Takeaway: Strong US expansion and ANDA portfolio growth drive revenue, though regulatory execution remains critical for future commercialization.
What just happened
Senores Pharmaceuticals reported strong financial growth for the fiscal year ending March 2026. The company’s consolidated revenue climbed to Rs 632.63 Cr from Rs 398.25 Cr in the previous year. Net profit more than doubled to Rs 121.53 Cr, resulting in an Earnings Per Share (EPS) of Rs 26.39. Alongside these results, the board approved the 'Senores Pharmaceuticals Employee Stock Option Scheme 2026' and appointed Mr. Viranchi Arvindbhai Shah as a Non-Executive Independent Director.
Why this matters
The company’s strategic shift to a direct-to-market US model is yielding results, with the US market now accounting for 68% of total revenue. By doubling its approved ANDA portfolio to 51 and integrating Zoraya Pharmaceuticals alongside a 75% stake in Apnar Pharma, Senores is building significant scale. The ongoing greenfield expansion at the Chhatral API facility from 25 MTPA to 169 MTPA is intended to ensure long-term supply security and margin stability.
Risks to watch
Success remains tethered to regulatory milestones. The company is awaiting key USFDA approvals for its expanded Chhatral facility and must effectively commercialize 30 pending ANDAs. Additionally, shareholders should monitor the integration of Amerisyn and Zoraya platforms, as financial performance relies heavily on scaling these new assets efficiently.
What to track next
Watch for updates on the Amerisyn joint venture, which is targeting federal procurement contracts in the US. Further, the commissioning of the new sterile manufacturing facility for injectables and biologics will be a key indicator of future capacity growth.